Johns Hopkins University School of Medicine
Baltimore, United States
Michelle A. Rudek, Pharm.D., Ph.D is a Professor of Oncology and Medicine at Johns Hopkins University. Dr. Rudek is a clinical pharmacologist whose research focuses on elucidating exposure-response relationships of anticancer agents. She directs her efforts towards preclinical and early phase drug development (i.e., Phase I clinical trials including brain cancer) and special populationswithin oncology including AIDS malignancy and organ dysfunction. She is the contact Principal Investigator on The Chesapeake-Ohio Pharmacokinetics Core for the NCI Experimental Therapeutics Clinical Trials Network and multi-Principal Investigator for The Johns Hopkins Translational Science Team (JHTST) and Consortium for ETCTN Studies.Dr. Rudek is a co-founder Geminus Therapeutics with Dr. Curt Civin at University of Maryland Baltimore with the intention of developing 2-Carbon-Linked Artemisinin Dimers (2C-ARTs) for the prevention and treatment of various cancers. She is the Subject Matter Expert in Pharmacology of the NCI’s Investigational Drug Steering Committee (IDSC) and Chair of the NCI’s IDSC Pharmacology Task Force. Dr. Rudek was the first non-physician to receive the NCI Michaele Christian Oncology Development Award.
